Cemiplimab Survivorship Epidemiology (CASE) Study
Cemiplimab Survivorship Epidemiology (CASE) Study
Sponsor: Regeneron Pharmaceuticals
Enrolling: Male and Female Patients
IRB Number: AAAS3659
U.S. Govt. ID: NCT03836105
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of the study is to determine the long-term effectiveness and safety of cemiplimab in patients diagnosed with Cutaneous Squamous Cell Carcinoma (CSCC, a type of skin cancer).
This study is closed
Richard Carvajal, MD
Do You Qualify?
Are you starting or receiving treatment with cemiplimab for Cutaneous Squamous Cell Carcinoma (CSCC)? Yes No
Are you 18 years of age or older? Yes No
Are you able to understand and complete study-related questionnaires? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator